Grail IPO

grail.com

Grail was founded in 2015 by Richard (Rick) Klausner, MD and Jeff Huber. The company filed its S-1 registration document with the SEC in September 2020 in advance of a planned Initial Public Offering. Subsequently in the same month, Illumia announced in a press release it had reached a definitive agreement to acquire Grail for $8 billion.

Grail is the developer of a pan-cancer screening test designed to detect cancer early. The company has raised approximately $2 billion in Venture Capital funding from investors including ARCH Venture Partners, Bezos Expeditions, Biomatics Capital, GV, Illumina, Foresite Capital Management, McKesson Ventures, Tencent, Amino Capital, Baillie Gifford, Decheng Capital, Dentsu Ventures, 6 Dimensions Capital, and Blue Pool Capital. Per company press releases, Grail last raised $390 million in May 2020 at a post-money valuation of $3.85 billion.

Founded2016
Total Funding to Date$2.02B
Register for Details

For more details on financing and valuation for Grail, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Click here to log in

Grail Ticker Symbol

Grail does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.

Grail Stock Price

The stock price for Grail will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).

Major Investors for Grail

Sequoia Capital China
Canada Pension Plan Investment Board
Illumina
Hillhouse Capital Group
HuangPu River Capital
SV Angel
PSP Investments

Grail Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
5/6/2020 Series D $4.26B $XXX.XX $XXX.XX
5/21/2018 Series C $3.2B $XXX.XX $XXX.XX
11/22/2017 Series B $2.35B $XXX.XX $XXX.XX
1/8/2016 Series A $212.5MM $XXX.XX $XXX.XX
Based on primary financings

Other companies like Grail in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$1.08B
Sector
 
 
Sector
Last Round Est. Valuation
$885.01MM
Sector
Last Round Est. Valuation
$1.34B